FDA Drugs (New Approvals & NDA)Original article
Bausch & Lomb Inc. - 732398 - 09/04/2026
RegulatoryNegative
AI Analysis
Summary
Bausch & Lomb received an FDA regulatory action related to CGMP and adulteration concerns in finished pharmaceuticals. The specific drug and details of the enforcement action are not detailed in the provided text.
Outcome Details
CGMP/Finished Pharmaceuticals/Adulterated
Importance:6/10
Sentiment:
-0.70
FDAManufacturingComplianceAdulterationCGMP
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on September 15, 2026 1:20 PM